Metabolic abnormalities in HIV-infected patients: An update

Current Infectious Disease Reports

Volumn 8, Issue 6, 2006, Pages 497-504

  Brown, Todd T ^a   Cofrancesco Jr , Joseph ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR PLUS LAMIVUDINE; ACETYLSALICYLIC ACID; AMPRENAVIR PHOSPHATE; ATAZANAVIR; ATORVASTATIN; BEZAFIBRATE; DOCOSAHEXAENOIC ACID; EFAVIRENZ; EMTRICITABINE; FENOFIBRATE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; ICOSAPENTAENOIC ACID; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; METFORMIN; NELFINAVIR; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; ROSUVASTATIN; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIET; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EXERCISE; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DISEASE; LACTIC ACIDOSIS; LIFESTYLE; LIVER FAILURE; LIVER TOXICITY; METABOLIC DISORDER; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION;

EID: 33750890926     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-006-0025-5     Document Type: Review

References (68)

1. Young J, Weber R, Rickenbach M, et al.: Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005, 10:585-591.
2. Cohen C, Nieto-Cisneros L, Zala C, et al.: Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin 2005, 21:1683-1692.
3. Wood R, Phanuphak P, Cahn P, et al.: Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004, 36:684-692.
4. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al.: Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005, 39:174-180.
5. Johnson M, Grinsztejn B, Rodriguez C, et al.: 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006, 20:711-718.
6. Rodriguez-French A, Boghossian J, Gray GE, et al.: The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004, 35:22-32.
7. Eron Jr J, Yeni P, Gathe Jr J, et al.: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006, 368:476-482.
8. Periard D, Telenti A, Sudre P, et al.: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999, 100:700-705.
9. Malan N, Krantz E, David N, et al.: Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
10. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191-201.
11. Moyle, G, Sabin, C, Cartledge, J, et al.: A 48-week, randomized open-label comparative study of tenofovir DF vs abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22-25, 2005.
12. Schewe CK, Maserati R, Wassmer G, et al.: Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment. Clin Infect Dis 2006, 42:145-147.
13. da Silva B, Albrecht M, Benson C, et al.: Improved metabolic profile with replacement of stavudine by tenofovir DF after 6 years of a lopinavir/ritonavir-based regimen. Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13-17, 2005.
14. Llibre JM, Domingo P, Perez MJ, et al.: Improvements in dyslipidemia at 48 weeks following substitution of stavudine with tenofovir DF. Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13-17, 2005.
15. Van Der Lee M, Vogel M, Schippers E, et al.: Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
16. Mallon PW, Miller J, Kovacic JC, et al.: Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men - a randomized, placebo-controlled study. AIDS 2006, 20:1003-1010.
17. Calza L, Manfredi R, Chiodo F: Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002, 30:26-31.
18. Rao A, D'Amico S, Balasubramanyam A, Maldonado M: Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. Am J Med Sci 2004, 327:315-318.
19. de Truchis, P: Treatment of hypertriglyceridemia in HIV-infected patients under HAART by polyunsaturated acids: a double blind randomized prospective trial in 122 patients. Presented at the 12th Conference of Retroviruses and Opportunistic Infections. Boston, MA; February 22-25, 2005.
20. Wohl DA, Tien HC, Busby M, et al.: Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertri-glyceridemia. Clin Infect Dis 2005, 41:1498-1504.
21. Gerber MT, Mondy KE, Yarasheski KE, et al.: Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis 2004, 39:419-425.
22. Dube MP, Wu JW, Aberg JA, et al.: Safety and Efficacy of Extended-release Niacin for the Treatment of Dyslipidemia in Patients with HIV-infection: a Prospective, Multicenter Study (ACTG 5148). Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13-17, 2005.
23. Aberg JA, Zackin RA, Brobst SW, et al.: A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with tipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005, 21:757-767.
24. Gerber J, Kitch D, Aberg JA, et al.: The safety and efficacy of fish oil in combination with fenofibrate in subjects on ART with hypertriglyceridemia who had an incomplete response to either agent alone: results of ACTG A5186. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
25. Calza L, Manfredi R, Colangeli V, et al.: Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005, 19:1051-1058.
26. Dube MP, Stein JH, Aberg JA, et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613-627.
27. Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002, 31:257-275.
28. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
29. Nightingale SL: From the Food and Drug Administration. JAMA 1997, 278:379.
30. Walli R, Herfort O, Michl GM, et al.: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-F173.
31. Dube MP: Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000, 31:1467-1475.
32. Brown TT, Cole SR, Li X, et al.: Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005, 165:1179-1184.
33. Danoff A, Shi Q, Justman J, et al.: Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. J Acquir Immune Defic Syndr 2005, 39:55-62.
34. American Diabetes Association: Clinical practice recommendations 2004. Diabetes Care 2004, 27(Suppl 1):S1-S150.
35. Justman JE, Benning L, Danoff A, et al.: Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003, 32:298-302.
36. Noor MA, Seneviratne T, Aweeka FT, et al.: Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002, 16:F1-F8.
37. Noor MA, Parker RA, O'Mara E, et al.: The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004, 18:2137-2144.
38. Lee GA, Seneviratne T, Noor MA, et al.: The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004, 18:641-649.
39. Lee GA, Rao MN, Schwarz JM, et al.: A single dose of amprenavir does not induce insulin resistance in healthy normal volunteers. Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13-17, 2005.
40. Lee GA, Mafong DD, Lo JC, et al.: Ritonavir Acutely Induces Insulin Resistance in Healthy Normal Volunteers. Presented at the 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Washington, DC; October 25-28, 2004.
41. Yan Q, Hruz PW: Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr 2005, 40:398-403.
42. Brown TT, Li X, Cole SR, et al.: Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005, 19:1375-1383.
43. Mynarcik DC, McNurlan MA, Steigbigel RT, et al.: Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000, 25:312-321.
44. Shlay JC, Visnegarwala F, Bartsch G, et al.: Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr 2005, 38:147-155.
45. Blumer RME, van Vonderen MGA, Sutinen J, et al.: Increased lipolysis and reduced peripheral glucose disposal without changes in body composition 3 months after initiating a NRTI-containing, but not a NRTI-sparing regimen in antiretroviral-naïve HIV-1-infected patients: results of a randomized clinical trial. Presented at the 88th Meeting of the Endocrine Society. Boston, MA; June 24-27, 2006.
46. Ranade K, Parker RA, Ploughman L, et al.: A single nucleotide polymorphism in the resistin gene is associated with adverse metabolic changes on HAART: an exploratory pharmacogenetic association study of A5005s, the metabolic sub-study of ACTG 384. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
47. American Diabetes Association: Clinical practice recommendations. Diabetes Care 2006, 29(Suppl 1):S1-S85.
48. Hadigan C, Meigs JB, Corcoran C, et al.: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32:130-139.
49. Mulligan K, Lo JC, Khatami H, Schambelan M.: Use of the oral glucose tolerance test to estimate insulin sensitivity in patients with HIV-infection. Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13-17, 2005.
50. Diop ME, Bastard JP, Meunier N, et al.: Inappropriate glycated hemoglobin values and hemolysis in HIV-infected patients. Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13-17, 2005.
51. Hadigan C, Corcoran C, Basgoz N, et al.: Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000, 284:472-477.
52. van Wijk JP, de Koning EJ, Cabezas MC, et al.: Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005, 143:337-346.
53. Mulligan K, Yang Y, Koletar S, et al.: Effects of metformin and rosiglitazone on body composition in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio: a randomized, placebo-controlled trial. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
54. Kohli R, Wanke C, Gorbach S, Shevitz A: A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
55. Carr A, Workman C, Carey D, et al.: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004, 363:429-438.
56. Sutinen J, Hakkinen AM, Westerbacka J, et al.: Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir Ther 2003, 8:199-207.
57. Hadigan C, Yawetz S, Thomas A, et al.: Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004, 140:786-794.
58. Slama L, Lanoy E, Valentin MA, et al.: Effect of pioglitazone on HIV-1 related lipoatrophy: a randomized double-blind placebo-controlled trial (ANRS 113) with 130 patients. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
59. Lebovitz HE, Austin MM, Blonde L, et al.: ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 2006, 12(Suppl 1):6-12.
60. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
61. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
62. Jerico C, Knobel H, Montero M, et al.: Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005, 28:132-137.
63. Bonfanti P, Ricci E, de Socio G, et al.: Metabolic syndrome: a real threat for HIV-positive patients?: Results from the SIMONE study. J Acquir Immune Defic Syndr 2006, 42:128-131.
64. Mondy K, Tong S, Kessels L, et al.: Metabolic syndrome in HIV within a representative U.S. patient population. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
65. Palella. F, Wang Z, Chu H, et al.: Correlates of the metabolic syndrome among HIV seropositive and seronegative men in the multicenter AIDS cohort study. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
66. Friis-Møller N, Reiss P, El-Sadr W, et al.: Exposure to PI and NNRTI and risk of myocardial infarction: results from the D:A:D Study. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
67. Lichtenstein K, Armon C, Buchacz K, et al.: Analysis of cardiovascular risk factors in the HIV outpatient study cohort. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
68. Currier J, Kendall M, Henry K, et al.: 3-year Follow-up of carotid intima-media thickness in HIV-infected and uninfected adults: ACTG 5078. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.